BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36549594)

  • 41. Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population.
    Li D; Shi Y; Li A; Cao D; Su H; Yang H; Zhi Q; Yang Y; Lan Z; Zhou T; You X; Hu G
    Breast Cancer; 2020 Nov; 27(6):1158-1167. PubMed ID: 32566972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predicting Openness of Communication in Families With Hereditary Breast and Ovarian Cancer Syndrome: Natural Language Processing Analysis.
    Baroutsou V; Cerqueira Gonzalez Pena R; Schweighoffer R; Caiata-Zufferey M; Kim S; Hesse-Biber S; Ciorba FM; Lauer G; Katapodi M;
    JMIR Form Res; 2023 Jan; 7():e38399. PubMed ID: 36656633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
    de Souza Timoteo AR; Gonçalves AÉMM; Sales LAP; Albuquerque BM; de Souza JES; de Moura PCP; de Aquino MAA; Agnez-Lima LF; Lajus TBP
    Breast Cancer Res Treat; 2018 Dec; 172(3):637-646. PubMed ID: 30159786
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines.
    Neben CL; Zimmer AD; Stedden W; van den Akker J; O'Connor R; Chan RC; Chen E; Tan Z; Leon A; Ji J; Topper S; Zhou AY
    J Mol Diagn; 2019 Jul; 21(4):646-657. PubMed ID: 31201024
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.
    Obstet Gynecol; 2019 Dec; 134(6):e143-e149. PubMed ID: 31764758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men.
    Chandrasekar T; Gross L; Gomella LG; Hegarty SE; Leong JY; Giri VN
    Eur Urol Oncol; 2020 Jun; 3(3):291-297. PubMed ID: 31278035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medical knowledge and information needs among women with pathogenic variants in moderate-risk genes for hereditary breast cancer attending genetic counseling at an academic hospital in Germany-A qualitative approach.
    Stracke C; Lemmen C; Rhiem K; Schmutzler R; Kautz-Freimuth S; Stock S
    J Genet Couns; 2022 Jun; 31(3):698-712. PubMed ID: 34837291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Breast Cancer: Genetics and Risk Assessment.
    Tejada-Bergés T
    Clin Obstet Gynecol; 2016 Dec; 59(4):673-687. PubMed ID: 27749364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Healthcare Predictors of Information Dissemination About Genetic Risks.
    Henderson V; Strayhorn SM; Bergeron NQ; Strahan DC; Ganschow PS; Khanna AS; Watson K; Hoskins K; Molina Y
    Cancer Control; 2022; 29():10732748221104666. PubMed ID: 35658635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.
    Shkedi-Rafid S; Gabai-Kapara E; Grinshpun-Cohen J; Levy-Lahad E
    Genet Med; 2012 Jul; 14(7):688-94. PubMed ID: 22481128
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
    Lee EG; Kang HJ; Lim MC; Park B; Park SJ; Jung SY; Lee S; Kang HS; Park SY; Park B; Joo J; Han JH; Kong SY; Lee ES
    Cancer Res Treat; 2019 Jan; 51(1):280-288. PubMed ID: 29747489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
    Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
    Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer risk management decision making for BRCA+ women.
    Leonarczyk TJ; Mawn BE
    West J Nurs Res; 2015 Jan; 37(1):66-84. PubMed ID: 24470135
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
    Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparing Outcomes of Genetic Counseling Options in Breast and Ovarian Cancer: An Integrative Review
.
    Fournier DM; Bazzell AF; Dains JE
    Oncol Nurs Forum; 2018 Jan; 45(1):96-105. PubMed ID: 29251290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
    Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
    BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.